Fibrocell Science, Inc. Announces Updated Investor Presentation

Marina Maher Communications LLCChristina Fuschetto, 212-485-6917orICRSherry Bertner, 646-277-1247

Fibrocell Science, Inc., has posted an updated investor presentation including updates on the pipeline, plans for expansion of manufacturing capacity and plans to reduce the cost of goods. The presentation can be accessed at .

Fibrocell Science, Inc. (OTCBB:FCSC.OB) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit .

Suggested Articles

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Kadmon has posted positive and more detailed data out of its so-called ROCKstar pivotal trial of KD025 in chronic graft-versus-host disease.

Clover is one of a clutch of organizations working to tackle COVID-19 by targeting a protein the novel coronavirus needs to enter host cells.